CADTH Canadian Drug Expert Committee final recommendation : indication: moderate to severe plaque psoriasis. Ixekizumab (Taltz -- Eli Lilly Canada Inc.) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Cost effectiveness.

Physical Description:

1 online resource (40 pages) : illustrations

Place of Publication:

Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2016.

Summary:

Ixekizumab (Taltz) is indicated for use in adult patients with active psoriatic arthritis (PsA) who have responded inadequately to or are intolerant to one or more conventional diseasemodifying antirheumatic drugs (DMARDs). Ixekizumab can be used alone or in combination with a conventional DMARD. The dosage form is 80 mg/mL solution in a pre-filled syringe or pen, intended for patients to self-administer subcutaneously. The recommended dose for adult PsA patients or PsA patients with coexistent mild plaque psoriasis is an initial dose of 160 mg (two 80 mg injections), followed by 80 mg given every four weeks. For PsA patients with coexistent moderate to severe plaque psoriasis, the dosing regimen for plaque psoriasis should be used (initial dose of 160 mg [two 80 mg injections], followed by 80 mg given every other week until week 12 and then every four weeks thereafter). At the manufacturer's submitted price of 1,544.82 per 80 mg dose, the first-year cost of ixekizumab is 21,627 in patients with PsA or PsA patients with coexistent mild plaque psoriasis and 26,262 in PsA patients with coexistent moderate to severe plaque psoriasis; thereafter, the annual maintenance cost of ixekizumab is 20,138 per patient. Ixekizumab was previously reviewed by CADTH in 2016 for the indication of moderate to severe plaque psoriasis. CADTH's Canadian Drug Expert Committee recommended listing ixekizumab with clinical criteria as follows: limited to patients with a documented inadequate response, contraindication, or intolerance to conventional systemic therapies such as methotrexate and cyclosporine, and treatment should be discontinued if a response to treatment with ixekizumab has not been demonstrated after 12 weeks. The manufacturer's submitted price for ixekizumab at the time of this CADTH Common Drug Review (CDR) submission was 1,519 per 80 mg dose. The manufacturer submitted a cost-utility analysis of ixekizumab compared with best supportive care (BSC) and biologics in patients with active PsA whose disease was not adequately controlled or who were intolerant to one or more conventional DMARDs. BSC was defined as conventional DMARDs, which included methotrexate, sulfasalazine, and leflunomide.

Notes:

Description based on publisher supplied metadata and other sources.